EA201992407A1 - Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf - Google Patents

Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf

Info

Publication number
EA201992407A1
EA201992407A1 EA201992407A EA201992407A EA201992407A1 EA 201992407 A1 EA201992407 A1 EA 201992407A1 EA 201992407 A EA201992407 A EA 201992407A EA 201992407 A EA201992407 A EA 201992407A EA 201992407 A1 EA201992407 A1 EA 201992407A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
tnf activity
imidazole derivatives
activity modulators
condensed pentacyclic
Prior art date
Application number
EA201992407A
Other languages
English (en)
Other versions
EA039049B1 (ru
Inventor
Дэниел Кристофер Брукингс
Тереса Де Аро Гарсия
Янн Форише
Хелен Трейси Хорсли
Мартин Клайв Хатчингс
Джеймс Эндрю Джонсон
Малькольм Маккосс
Мэнъян Сюань
Чжаонин Чжу
Original Assignee
Юсб Байофарма Спрл
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201992407(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсб Байофарма Спрл, Санофи filed Critical Юсб Байофарма Спрл
Publication of EA201992407A1 publication Critical patent/EA201992407A1/ru
Publication of EA039049B1 publication Critical patent/EA039049B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описано соединение формулы (I), определенной в настоящем изобретении, или его фармацевтически активная соль, которые являются активными модуляторами активности TNF человека и поэтому полезны для лечения и/или предупреждения различных заболеваний человека, включая аутоиммунные и воспалительные нарушения; неврологические и нейродегенеративные нарушения; боль и ноцицептивные нарушения; сердечно-сосудистые нарушения; метаболические нарушения; глазные нарушения и онкологические нарушения.
EA201992407A 2017-04-25 2018-04-24 Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf EA039049B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
EA201992407A1 true EA201992407A1 (ru) 2020-04-06
EA039049B1 EA039049B1 (ru) 2021-11-26

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992407A EA039049B1 (ru) 2017-04-25 2018-04-24 Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf

Country Status (34)

Country Link
US (3) US10980814B2 (ru)
EP (2) EP3939980B1 (ru)
JP (2) JP7083358B2 (ru)
KR (1) KR102565132B1 (ru)
CN (1) CN110582495B (ru)
AR (1) AR111426A1 (ru)
AU (1) AU2018259040B2 (ru)
BR (1) BR112019020314A2 (ru)
CA (1) CA3058980A1 (ru)
CL (1) CL2019002875A1 (ru)
CO (1) CO2019012856A2 (ru)
CR (1) CR20190526A (ru)
DK (1) DK3615534T3 (ru)
EA (1) EA039049B1 (ru)
ES (2) ES2956555T3 (ru)
HR (1) HRP20211927T1 (ru)
HU (1) HUE056593T2 (ru)
IL (1) IL269890B (ru)
LT (1) LT3615534T (ru)
MA (2) MA49055B1 (ru)
MX (1) MX2019012443A (ru)
MY (1) MY197212A (ru)
NZ (1) NZ758198A (ru)
PE (1) PE20200662A1 (ru)
PH (1) PH12019502182A1 (ru)
PL (2) PL3615534T3 (ru)
PT (2) PT3615534T (ru)
RS (1) RS62596B1 (ru)
SG (1) SG11201908871SA (ru)
SI (1) SI3615534T1 (ru)
TW (1) TWI801378B (ru)
UY (1) UY37700A (ru)
WO (1) WO2018197503A1 (ru)
ZA (1) ZA201906255B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017167995A1 (en) * 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused hexacyclic imidazole derivatives as modulators of tnf activity
CN113227097B (zh) * 2018-10-24 2023-09-08 Ucb生物制药有限责任公司 作为tnf活性调节剂的稠合五环咪唑衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858983B1 (en) * 2012-06-11 2018-04-18 UCB Biopharma SPRL Tnf-alpha modulating benzimidazoles
CA2877550C (en) * 2012-07-13 2020-09-08 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI719949B (zh) 2014-10-03 2021-03-01 比利時商Ｕｃｂ生物製藥公司 稠合五環咪唑衍生物
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Also Published As

Publication number Publication date
MY197212A (en) 2023-06-01
EP3615534B1 (en) 2021-09-15
US20230250105A1 (en) 2023-08-10
MX2019012443A (es) 2020-01-13
PH12019502182A1 (en) 2020-06-08
EP3939980A1 (en) 2022-01-19
LT3615534T (lt) 2021-11-25
UY37700A (es) 2018-11-30
HUE056593T2 (hu) 2022-02-28
MA49055A (fr) 2021-05-05
ES2893807T3 (es) 2022-02-10
US20200046723A1 (en) 2020-02-13
CN110582495A (zh) 2019-12-17
KR102565132B1 (ko) 2023-08-08
PL3615534T3 (pl) 2022-01-31
JP2020517637A (ja) 2020-06-18
JP2022116233A (ja) 2022-08-09
CA3058980A1 (en) 2018-11-01
ZA201906255B (en) 2021-01-27
SG11201908871SA (en) 2019-10-30
BR112019020314A2 (pt) 2020-04-28
IL269890B (en) 2022-03-01
ES2956555T3 (es) 2023-12-22
RS62596B1 (sr) 2021-12-31
DK3615534T3 (da) 2021-10-18
PT3615534T (pt) 2021-10-21
CN110582495B (zh) 2022-04-01
CR20190526A (es) 2020-01-07
US20210252012A1 (en) 2021-08-19
PL3939980T3 (pl) 2024-02-05
JP7299382B2 (ja) 2023-06-27
SI3615534T1 (sl) 2022-01-31
MA49055B1 (fr) 2021-12-31
TWI801378B (zh) 2023-05-11
EA039049B1 (ru) 2021-11-26
AU2018259040B2 (en) 2022-04-28
HRP20211927T1 (hr) 2022-03-18
KR20190141200A (ko) 2019-12-23
MA57699B1 (fr) 2023-11-30
WO2018197503A1 (en) 2018-11-01
AU2018259040A1 (en) 2019-10-31
TW201841918A (zh) 2018-12-01
CO2019012856A2 (es) 2020-01-17
PE20200662A1 (es) 2020-06-11
CL2019002875A1 (es) 2020-03-06
JP7083358B2 (ja) 2022-06-10
NZ758198A (en) 2024-01-26
US10980814B2 (en) 2021-04-20
PT3939980T (pt) 2023-08-07
EP3939980B1 (en) 2023-07-26
AR111426A1 (es) 2019-07-10
EP3615534A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
EA201790734A1 (ru) Конденсированные пентациклические производные имидазола
EA201792688A1 (ru) Производные бензоксазинона и его аналоги в качестве модуляторов активности tnf
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
EA201500133A1 (ru) Производные имидазопиразина в качестве модуляторов активности tnf
MX2021009673A (es) Moduladores de ror-gamma.
CA2931589C (en) Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201892153A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
EP4299126A3 (en) Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
TR201910983T4 (tr) Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.